Loading...
XNASIBRX
Market cap1.95bUSD
Dec 23, Last price  
2.67USD
1D
1.91%
1Q
-25.83%
Jan 2017
-53.32%
IPO
-92.37%
Name

Immunitybio Inc

Chart & Performance

D1W1MN
XNAS:IBRX chart
P/E
—
P/S
3,134.31
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
45.08%
Rev. gr., 5y
67.62%
Revenues
622k
+159.17%
641,000236,00044,00045,00047,0002,202,000605,000934,000240,000622,000
Net income
-583m
L+39.75%
-6,213,000-236,876,000-120,809,000-96,423,000-96,226,000-160,158,000-224,187,000-349,848,000-417,320,000-583,196,000
CFO
-367m
L+8.67%
-668,000-5,354,000-25,305,000-38,593,000-48,780,000-63,381,000-152,109,000-171,724,000-274,419,000-337,509,000-366,757,000
Earnings
Mar 17, 2025

Profile

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
URL
https://immunitybio.com/
IPO date
Jul 28, 2015
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
622
159.17%
240
-74.30%
934
54.38%
Cost of revenue
232,366
272,341
195,958
Unusual Expense (Income)
NOPBT
(231,744)
(272,101)
(195,024)
NOPBT Margin
Operating Taxes
(40)
34
9
Tax Rate
NOPAT
(231,704)
(272,135)
(195,033)
Net income
(583,196)
39.75%
(417,320)
19.29%
(349,848)
56.05%
Dividends
Dividend yield
Proceeds from repurchase of equity
110,103
59,811
160,466
BB yield
-4.31%
-2.95%
-6.78%
Debt
Debt current
5,308
434,551
302,247
Long-term debt
766,665
339,823
383,496
Deferred revenue
Other long-term liabilities
310,627
22,093
249
Net debt
504,620
661,490
361,852
Cash flow
Cash from operating activities
(366,757)
(337,509)
(274,419)
CAPEX
(30,584)
(99,391)
(33,563)
Cash from investing activities
(30,470)
27,297
(84,886)
Cash from financing activities
558,341
233,613
505,443
FCF
(224,940)
(342,415)
(223,521)
Balance
Cash
266,462
107,184
317,116
Long term investments
891
5,700
6,775
Excess cash
267,322
112,872
323,844
Stockholders' equity
(2,960,557)
(2,380,756)
(1,963,617)
Invested Capital
3,412,034
2,676,802
2,365,617
ROIC
ROCE
EV
Common stock shares outstanding
508,636
399,900
389,234
Price
5.02
-0.99%
5.07
-16.61%
6.08
-54.39%
Market cap
2,553,351
25.94%
2,027,495
-14.33%
2,366,544
-53.67%
EV
3,059,021
2,686,492
2,726,656
EBITDA
(213,232)
(253,841)
(180,786)
EV/EBITDA
Interest
129,198
63,515
14,849
Interest/NOPBT